PR Newswire·Apr 30, 2026, 8:00 AM ET

Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer

The Israel Patent Office granted Genprex, Inc. a patent for Reqorsa Gene Therapy in combination with PD-1 antibodies to treat cancer.
This approval expands Genprex's existing patent portfolio, which previously covered the same combination in the U.S., Japan, Mexico, Russia, Australia, Chile, China, Singapore, & Europe.
Reqorsa is initially being developed alongside approved cancer drugs to target lung cancer, with preclinical data showing complementarity with targeted drugs & immunotherapies.
The Israeli Ministry of Health reports a 33% increase in lung cancer cases over a decade, with the disease causing 21.1% of cancer deaths among Israeli men & 11.8% among Israeli women.
Genprex's lead candidate, Reqorsa, is currently evaluated in two clinical trials for NSCLC & SCLC, receiving FDA Fast Track Designation for both & Orphan Drug Designation for the SCLC program.
The company utilizes its non-viral Oncoprex Delivery System to administer gene-expressing plasmids via intravenous injection to tumor cells.
Genprex also develops diabetes therapies using an AAV vector infusion process designed to transform alpha cells into functional beta-like cells or rejuvenate exhausted beta cells.
The press release includes standard forward-looking statement disclaimers regarding clinical development, regulatory approvals, & financial status risks.